drug           SLEM                    target    CT outcome      [reference]  therapy level


Ipilimumab    -54.090000000000003411   CTLA-4    active           [9]         single therapy
Pembrolizumab -51.170999999999992269   PD-1      active          [11]         single therapy
Bevacizumab   -59.963999999999998636   VEGF      active           [4]         bevacizumab + bicalutamide
Blinatumomab  -45.503999999999997783   CD19      no data 

Pertuzumab    -29.942590944545145248   HER2      no activity     [12]         single therapy
Denosumab     -27.308537974119431624   RANKL     no activity      [7]         single therapy
Daratumumab   -24.235988182835342286   CD38      no  activity     [6]         single therapy
Trastuzumab   -22.316251479584529704   HER2      no  activity    [13]         single therapy

Aflibercept   -42.588000000000000966   CD19      no activity      [1]         aflibercept + docetaxel + prednisolone
Atezolizumab  -42.316000000000002501   PD-L1     active           [2]         atezolizumab + enzalutamide
Durvalumab    -48.450000000000002842   PD-L1     active           [8]         durvalumab + olaparib
Nivolumab     -46.587000000000003297      active          [10]         nivolumab + docetaxel

Avelumab      failed                   PD-L1     no activity      [3]         single therapy


Ipilimumab, Pembrolizumab, Bevacizumab, Atezolizumab, Durvalumab, Nivolumab show activity in clinical trials.



1. Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Fléchon A, Skoneczna I, Orlandi F, Gravis G, Matveev V, Bavbek S, Gil T, Viana L, Arén O, Karyakin O, Elliott T, Birtle A, Magherini E, Hatteville L, Petrylak D, Tombal B, Rosenthal M; VENICE investigators. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol. 2013 Jul;14(8):760-8. doi: 10.1016/S1470-2045(13)70184-0. Epub 2013 Jun 4. PMID: 23742877.

2. Powles T, Yuen KC, Gillessen S, Kadel EE 3rd, Rathkopf D, Matsubara N, Drake CG, Fizazi K, Piulats JM, Wysocki PJ, Buchschacher GL Jr, Alekseev B, Mellado B, Karaszewska B, Doss JF, Rasuo G, Datye A, Mariathasan S, Williams P, Sweeney CJ. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat Med. 2022 Jan;28(1):144-153. doi: 10.1038/s41591-021-01600-6. Epub 2022 Jan 10. PMID: 35013615; PMCID: PMC9406237.

3. Madan RA, Redman JM, Karzai F, Dahut WL, Cordes L, Fakhrejahani F, Vu T, Sheikh N, Schlom J, Gulley JL. Avelumab in Men With Metastatic Castration-Resistant Prostate Cancer, Enriched for Patients Treated Previously With a Therapeutic Cancer Vaccine. J Immunother. 2023 May 1;46(4):145-151. doi: 10.1097/CJI.0000000000000459. Epub 2023 Feb 24. PMID: 36821354; PMCID: PMC10072211.

4. McKay RR, Zurita AJ, Werner L, Bruce JY, Carducci MA, Stein MN, Heath EI, Hussain A, Tran HT, Sweeney CJ, Ross RW, Kantoff PW, Slovin SF, Taplin ME. A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy. J Clin Oncol. 2016 Jun 1;34(16):1913-20. doi: 10.1200/JCO.2015.65.3154. Epub 2016 Apr 4. PMID: 27044933; PMCID: PMC5321094.

5. Fucà G, Spagnoletti A, Ambrosini M, de Braud F, Di Nicola M. Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy. ESMO Open. 2021 Feb;6(1):100046. doi: 10.1016/j.esmoop.2020.100046. Epub 2021 Jan 25. PMID: 33508733; PMCID: PMC7841318.

6. Siddiqui BA, Chapin BF, Jindal S, Duan F, Basu S, Yadav SS, Gu AD, Espejo AB, Kinder M, Pettaway CA, Ward JF, Tidwell RSS, Troncoso P, Corn PG, Logothetis CJ, Knoblauch R, Hutnick N, Gottardis M, Drake CG, Sharma P, Subudhi SK. Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor). J Immunother Cancer. 2023 Mar;11(3):e006262. doi: 10.1136/jitc-2022-006262. PMID: 36948506; PMCID: PMC10040066.

7. Hegemann M, Bedke J, Stenzl A, Todenhöfer T. Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience. Ther Adv Urol. 2017 Feb 6;9(3-4):81-88. doi: 10.1177/1756287216686018. PMID: 28392837; PMCID: PMC5378096.

8. Karzai F, VanderWeele D, Madan RA, Owens H, Cordes LM, Hankin A, Couvillon A, Nichols E, Bilusic M, Beshiri ML, Kelly K, Krishnasamy V, Lee S, Lee MJ, Yuno A, Trepel JB, Merino MJ, Dittamore R, Marté J, Donahue RN, Schlom J, Killian KJ, Meltzer PS, Steinberg SM, Gulley JL, Lee JM, Dahut WL. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J Immunother Cancer. 2018 Dec 4;6(1):141. doi: 10.1186/s40425-018-0463-2. PMID: 30514390; PMCID: PMC6280368.

9. Fizazi K, Drake CG, Beer TM, Kwon ED, Scher HI, Gerritsen WR, Bossi A, den Eertwegh AJMV, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Danielli R, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, McHenry MB, Chen A, Logothetis C; CA184-043, Investigators. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. 2020 Dec;78(6):822-830. doi: 10.1016/j.eururo.2020.07.032. Epub 2020 Aug 15. PMID: 32811715; PMCID: PMC8428575.

10. Fizazi K, González Mella P, Castellano D, Minatta JN, Rezazadeh Kalebasty A, Shaffer D, Vázquez Limón JC, Sánchez López HM, Armstrong AJ, Horvath L, Bastos DA, Amin NP, Li J, Unsal-Kacmaz K, Retz M, Saad F, Petrylak DP, Pachynski RK. Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial. Eur J Cancer. 2022 Jan;160:61-71. doi: 10.1016/j.ejca.2021.09.043. Epub 2021 Nov 18. PMID: 34802864.

11. Tucker MD, Zhu J, Marin D, Gupta RT, Gupta S, Berry WR, Ramalingam S, Zhang T, Harrison M, Wu Y, Healy P, Lisi S, George DJ, Armstrong AJ. Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer. Cancer Med. 2019 Aug;8(10):4644-4655. doi: 10.1002/cam4.2375. Epub 2019 Jul 3. PMID: 31270961; PMCID: PMC6712455.

12. Agus DB, Sweeney CJ, Morris MJ, Mendelson DS, McNeel DG, Ahmann FR, Wang J, Derynck MK, Ng K, Lyons B, Allison DE, Kattan MW, Scher HI. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol. 2007 Feb 20;25(6):675-81. doi: 10.1200/JCO.2006.07.0649. PMID: 17308272.

13. Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, Majeski S, Rosenblum M, Kane M, Chen L, Crawford ED. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate. 2004 Sep 1;60(4):332-7. doi: 10.1002/pros.20065. PMID: 15264245.
